Q-omics provides the consensus-scored PRSS12 profile across patient tissues and cancer cell-line models. PRSS12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRSS12 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PRSS12 RNA expression shows 15,014 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUAD, and THYM as cancer lineages where PRSS12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS12 survival associations across molecular data types. PRSS12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS12 RNA expression–survival associations across cancer types. High PRSS12 expression shows unfavorable associations in KIRP, SKCM and SCLC, but favorable associations in HNSC, LUSC and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PRSS12 RNA expression.
This table summarizes PRSS12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRSS12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS12 shows lower tumor expression in LUAD, COAD, BRCA and LUSC and higher tumor expression in STAD and PAAD. The LUAD box plot shows higher PRSS12 RNA expression in normal versus tumor tissue (log2 FC = −2.148, t-test p < 0.001).
This table shows molecular features associated with PRSS12 in patient tissues and cancer cell lines. In patient samples, PRSS12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
